HM15275 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called HM15275 to determine its safety and effectiveness in helping people who are overweight or obese lose weight. The study compares HM15275 to a placebo (a look-alike injection with no active drug) to evaluate its efficacy over 36 weeks. Suitable candidates for this trial include individuals with a body mass index (BMI) of 30 or above, or a BMI of 27 or above with at least one weight-related health issue, who have not experienced significant weight changes recently. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to the development of a potentially effective weight-loss solution.
Do I need to stop taking my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. However, you cannot have taken weight loss drugs in the 90 days before the screening.
Is there any evidence suggesting that HM15275 is likely to be safe for humans?
Research has shown that HM15275 is generally safe for people. In studies, participants took doses up to 4 mg without experiencing serious side effects. The safety profile of HM15275 is similar to other treatments used to manage blood sugar levels, indicating that most people did not encounter unexpected side effects. These findings suggest that HM15275 could be a promising treatment for obesity, with a safety record that supports further testing.12345
Why do researchers think this study treatment might be promising for obesity?
Most treatments for obesity focus on appetite suppression or inhibiting fat absorption, like orlistat or GLP-1 receptor agonists. But HM15275 works differently, targeting the body's metabolic processes to enhance energy expenditure and reduce fat accumulation. Administered via subcutaneous injection, it's designed to not only aid in weight loss but also potentially improve metabolic health markers. Researchers are excited because this novel approach could offer an effective alternative for those who struggle with existing options.
What evidence suggests that HM15275 might be an effective treatment for obesity?
Studies have shown that HM15275, which participants in this trial may receive, can help people lose a significant amount of weight. In earlier research, participants lost nearly 5% of their body weight after just four weeks, with some losing up to 10%. In animal studies, HM15275 led to a 39.9% reduction in body weight, proving more effective than other treatments tested. These results suggest that HM15275 could be a strong option for people struggling with obesity. The treatment targets specific parts of the body that control hunger and fat storage.12467
Are You a Good Fit for This Trial?
This trial is for individuals who are obese or overweight but do not have diabetes. Participants will be involved in the study for 36 weeks to assess the effectiveness and safety of a new treatment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive HM15275 or placebo via subcutaneous injection for 36 weeks, including a dose-titration phase
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- HM15275
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hanmi Pharmaceutical Company Limited
Lead Sponsor
Young Choi
Hanmi Pharmaceutical Company Limited
Chief Medical Officer since 2023
PhD in Pharmacology from Yonsei University
Jae-Hyun Park
Hanmi Pharmaceutical Company Limited
Chief Executive Officer since 2024
MD from Seoul National University